| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Jiangsu Lianhuan Pharmaceutical Co. Ltd (SHG: 600513)
600513 Technical Analysis
2
| As on 17th Apr 2025 600513 STOCK Price closed @ 9.41 and we RECOMMEND Buy for LONG-TERM with Stoploss of 9.31 & Strong Sell for SHORT-TERM with Stoploss of 11.00 we also expect STOCK to react on Following IMPORTANT LEVELS. |
600513STOCK Price
| Open | 9.30 | Change | Price | % |
| High | 9.44 | 1 Day | 0.06 | 0.64 |
| Low | 9.26 | 1 Week | 0.24 | 2.62 |
| Close | 9.41 | 1 Month | -0.10 | -1.05 |
| Volume | 4606203 | 1 Year | -0.42 | -4.27 |
| 52 Week High 13.61 | 52 Week Low 7.14 | ||||
SHG China Most Active Stocks
| 600705 | 3.47 | 0.29% |
| 600811 | 0.36 | -2.70% |
| 601933 | 5.81 | -3.17% |
| 600300 | 4.33 | 5.87% |
| 600575 | 3.98 | 9.94% |
| 603128 | 7.96 | 9.94% |
| 601288 | 5.37 | 0.00% |
| 601899 | 17.82 | 0.45% |
| 600157 | 1.36 | 0.00% |
| 601008 | 6.15 | -5.67% |
SHG China Top Gainers Stocks
SHG China Top Losers Stocks
| 600513 Daily Charts |
600513 Intraday Charts |
Whats New @ Bazaartrend |
600513 Free Analysis |
|
|
600513 Important Levels Intraday
| RESISTANCE | 9.76 |
| RESISTANCE | 9.65 |
| RESISTANCE | 9.58 |
| RESISTANCE | 9.51 |
| SUPPORT | 9.31 |
| SUPPORT | 9.24 |
| SUPPORT | 9.17 |
| SUPPORT | 9.06 |
600513 Forecast April 2025
| 4th UP Forecast | 17.16 |
| 3rd UP Forecast | 14.67 |
| 2nd UP Forecast | 13.14 |
| 1st UP Forecast | 11.6 |
| 1st DOWN Forecast | 7.22 |
| 2nd DOWN Forecast | 5.68 |
| 3rd DOWN Forecast | 4.15 |
| 4th DOWN Forecast | 1.66 |
600513 Weekly Forecast
| 4th UP Forecast | 11.03 |
| 3rd UP Forecast | 10.51 |
| 2nd UP Forecast | 10.19 |
| 1st UP Forecast | 9.87 |
| 1st DOWN Forecast | 8.95 |
| 2nd DOWN Forecast | 8.63 |
| 3rd DOWN Forecast | 8.31 |
| 4th DOWN Forecast | 7.79 |
600513 Forecast2025
| 4th UP Forecast | 24.23 |
| 3rd UP Forecast | 19.48 |
| 2nd UP Forecast | 16.54 |
| 1st UP Forecast | 13.6 |
| 1st DOWN Forecast | 5.22 |
| 2nd DOWN Forecast | 2.28 |
| 3rd DOWN Forecast | -0.66 |
| 4th DOWN Forecast | -5.41 |
Jiangsu Lianhuan Pharmaceutical Co. Ltd ( SHG China Symbol : 600513 )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
600513 Business Profile
Jiangsu Lianhuan Pharmaceutical Co., Ltd. manufactures and sells chemical raw materials, preparations, and organic intermediates in China. The company offers urinary system drugs, antihistamines, cardiovascular drugs, steroid hormones, antibiotics, and other products. Its products portfolio comprises eplet, terfenadine, ebastine tablets, felodipine tablets, felodipine sustained-release capsules, simvastatin tablets, danazol capsules and suppositories, metformin gliclazide tablets, lumbrokinase capsules, balofloxacin tablets, and sertraline hydrochloride; and APIs. It exports its products to approximately 20 countries, such as Europe, the United States, Southeast Asia, and Australia. The company was founded in 2000 and is based in Yangzhou, China. Address: No. 21, Wenfeng Road, Yangzhou, China, 225009
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service